Company: BDRX
Filing Date: 2025-05-01
Form Type: DRS
Source: 0001214659-25-006756
Chunk: 12

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-01
Form: DRS
Chunk 12
---
 Deferred Shares of £0.00005 nominal value each,
each the November Subdivision, which became effective on November 25, 2024 and (y) adopt new Articles of Association, which made consequential
amendments to the existing Articles of Association of the Company to reflect the November Subdivision. As is standard for deferred shares,
each C Deferred Share has very limited rights and is effectively valueless. The C Deferred Shares have the rights and restrictions as
set out in the Articles of Association and do not entitle the holder thereof to receive notice of or attend and vote at any general meeting
of the Company or to receive a dividend or other distribution.

The change in the number of
Ordinary Shares resulting from the reverse stock split and change in the number of Depositary Shares (and the underlying Ordinary Shares)
resulting from the change in ratio, including any changes resulting from fractional Depositary Shares not being issued to holders in connection
with the Depositary Share ratio change, has been applied retroactively to all share and per share amounts presented in this prospectus,
to the extent applicable. As a result of retroactively applying changes resulting from fractional Depositary Shares not being issued to
holders in connection with the Depositary Share ratio change, the amount of Ordinary Shares issued in prior transactions may not equal
the amount of Depositary Shares such Depositary Shares are currently exercisable for.

| 2 |

<div align='center'>MARKET AND INDUSTRY DATA</div>

This
prospectus contains estimates, projections and other information concerning our industry, our business and the market for our product
candidates. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject
to uncertainties, and actual events or circumstances may differ materially from events and circumstances that are assumed in this information.
Unless otherwise expressly stated, we obtained this industry, business, market and other data from our own internal estimates and research
as well as from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry,
medical and general publications, government data and similar sources. While we believe our internal company research as to such matters
is reliable and the market definitions are appropriate, neither such research nor these definitions have been verified by any independent
source.

In
addition, assumptions and estimates of our and our industry’s future performance are necessarily subject to a high degree of uncertainty
and risk due to a variety of factors, including those described in the section titled “Risk Factors.”